GuruFocus · ABBV · October 17, 2026

SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026

Get the app for more

Explore stock news, insights and company research.